Table S 1 Associations between AXL expression and

Table S 1: Associations between AXL expression and chemoresponse in 170 OSC patient tumors AXL H-score Score Distribution (n) 3 2 1 Chemoresponse Mean Score (100%-76%) (75%-51%) (50%-21%) Chemoresistant 2. 3 26 21 8 Chemosensitive 1. 9** 24 18 23 No Recurrence 1. 6*** 13 9 14 Asterisk indicates significant difference in AXL histology score from chemoresistant (**P = 0. 0045, ***P = 0. 001). 0 (20%-0%) 0 5 9 Table S 2: Multivariate logistic regression to predict chemoresistance Prognostic Factor Odds Ratio 95% confidence interval P-value AXL 2. 217 1. 148 - 4. 283 0. 0177 Grade 7. 115 1. 612 - 31. 400 0. 0096 c Debulking Status 2. 870 1. 478 - 5. 576 0. 0019 a AXL high (>71%) vs AXL low (<70%). b High-grade vs. low-grade. c No gross residual disease vs. measurable disease. a b

Table S 3: Clinical and Pathological Characteristics of Patient Derived Ov. Ca Sample ID Sample Type POV 71 h. TERT Immortalized primary cell line PB 1 NEO 02 NEO 07 NEO 06 NEO 08 NEO 13 Patientderived xenograft Patient tumor biopsy for RNA-Seq. Histology OS PFS Stage Subtype (months) Chemoresistant Germline Mutation HGOSC IIIC 13. 8 10. 5 Y BRCA 2 c. 3847 del. TG TP 53 c. 645 T>G mosaic VUS MSH 2 c. 434 T>C VUS HGOSC IIIC 42. 1 9. 7 Y none HGOSC IIIC AWD 10. 9 N PMS 2 c. 936 G>A VUS HGSOC IIIC AWD 7. 6 Y none HGSOC IIIC 24. 4 7. 9 Y none HGSOC IIIC AWD N/A N BRCA 1 c. 125 G>T CDK 4 p. V 260 E VUS HGSOC IVA AWD N/A N none HGSOC IIIC AWD N/A N none HGOSC = High grade serious ovarian cancer, OS = Overall survival, PFS = Progression free survival, AWD = Alive with disease